Monograph Details
|
|
Nutrition
> Electrolyte disturbances
|
|
K-LYTE DS |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Potassium (as bicarbonate and citrate) 50mEq; effervescent tabs for soln; lime and orange flavor. |
| Also |
|
• K-LYTE
|
| Indications |
|
Hypokalemia, including that caused by diuretics. Digitalis intoxication without AV block. |
| Children |
|
Not recommended. |
| Adults |
|
Prophylaxis: 25mEq daily. Treatment: 50–100mEq daily in divided doses. Both, dissolve each tab in 4–8oz of water and sip slowly over 5–10 minutes after meals. |
| Contraindications |
|
Hyperkalemia. Chronic renal disease. Acute dehydration. Heat cramps. Severe tissue destruction. Adrenal insufficiency. Familial periodic paralysis. Acidosis (potassium chloride products). Alkalosis (potassium bicarbonate products). Tablets: Esophageal compression due to enlarged left atrium. Decreased GI motility. |
| Precautions |
|
Discontinue if GI bleed, ulceration, or other disturbances occur. Renal or cardiac disease. Monitor potassium level, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Hyperkalemia with ACE inhibitors, spironolactone, triamterene, amiloride, and potassium-containing salt substitutes. Anticholinergics, other agents that decrease GI motility increase risk of serious GI reactions with tablets. |
| Adverse Reactions |
|
Hyperkalemia, GI discomfort and irritation, diarrhea, rash (rare). Tablets: Esophageal and GI ulceration, bleeding, obstruction, perforation. |
| How Supplied |
K-Lyte—30, 100, 250
DS—30, 100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
